Evidence map›Paper›PMID 31903153›Full record

ArticleTheranostics2020

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.

Stephanie S Kim, Shili Xu, Jing Cui, Soumya Poddar, Thuc M Le, Hovhannes Hayrapetyan, Luyi Li, Nanping Wu, Alexandra M Moore, Lei Zhou and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Stephanie S KimDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Shili XuDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Jing CuiDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Soumya PoddarAhmanson Translational Imaging Division, UCLA, Los Angeles, CA, 90095, USA.
Thuc M LeAhmanson Translational Imaging Division, UCLA, Los Angeles, CA, 90095, USA.
Hovhannes HayrapetyanDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Luyi LiDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Nanping WuDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Alexandra M MooreDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Lei ZhouDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Alice C YuDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Amanda M DannDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Irmina A ElliottDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
Evan R AbtAhmanson Translational Imaging Division, UCLA, Los Angeles, CA, 90095, USA.
Woosuk KimAhmanson Translational Imaging Division, UCLA, Los Angeles, CA, 90095, USA.
David W DawsonDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA.
Caius G RaduAhmanson Translational Imaging Division, UCLA, Los Angeles, CA, 90095, USA.
Timothy R DonahueDepartment of Surgery, UCLA, Los Angeles, CA, 90095, USA.
UCLA Medical Center · USUniversity of California, Los Angeles · USChina Medical University · CNUCLA Jonsson Comprehensive Cancer CenterUnion Hospital · CN

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
GASTROENTEROLOGYT32DK007180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENSEN, DENNIS MICHAEL · 1986 to 2025
$10.0M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS T32 CA009120NIDDK NIH HHS T32 DK007180
6 · The paper itself

Abstract

Arginine (Arg) deprivation is a promising therapeutic approach for tumors with low argininosuccinate synthetase 1 (ASS1) expression. However, its efficacy as a single agent therapy needs to be improved as resistance is frequently observed.

Indexed as

AnimalsAntineoplastic AgentsArginineArgininosuccinate SynthaseCarcinoma, Pancreatic DuctalCell Line, TumorFemaleHistone Deacetylase InhibitorsHistone DeacetylasesHumansHydrolasesMaleMiceMice, Inbred NODMice, SCIDMiddle AgedADI PEG20Antineoplastic AgentsArginineArgininosuccinate SynthaseHistone Deacetylase InhibitorsHistone DeacetylasesHydrolasesPanobinostatPolyethylene Glycolsarginine deprivationDNA damageHDAC inhibitorpancreatic cancersynthetic lethality

Identifiers

PMID31903153
PMCPMC6929997
OpenAlexW2992575520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.